GAB3 suppresses lung adenocarcinoma progression by inhibiting the MAPK signaling and potentiating CD8+ T cell immunity
Cancer Letters · 2026-07 · 651 · 218532
DOI: 10.1016/j.canlet.2026.218532 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Letters, 2026-07. Verfasst von Di Wang und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Scien…. Hauptthemen laut MEDLINE: Adenocarcinoma of Lung, Lung Neoplasms, CD8-Positive T-Lymphocytes, Adaptor Proteins, Signal Transducing. Die Arbeit nennt 33 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Beijing Natural Science Foundation.
Abstract (Originalsprache)
Lung adenocarcinoma (LUAD) remains a leading cause of cancer mortality. Although targeted therapies and immunotherapies have improved outcomes, many patients exhibit limited responses due to primary or acquired resistance, underscoring the need to identify novel molecular targets. The Gab family of scaffolding adaptors, including GAB1 and GAB2, are recognized oncogenic regulators, whereas the role of GAB3, implicated in immune cell activation, is poorly defined in solid tumors. Here, we identify GAB3 as a novel tumor suppressor in LUAD. Pan-cancer analysis revealed frequent GAB3 downregulation, and high GAB3 expression was associated with favorable prognosis. Functionally, GAB3 overexpression suppressed LUAD cell proliferation, migration, invasion, and tumor growth in vitro and in vivo. Mechanistically, GAB3 interacted with LYN kinase to inhibit the MAPK signaling pathway and reverse epithelial-mesenchymal transition (EMT). In addition, GAB3 remodeled the tumor immune microenvironment, enhanced CXCL10 secretion, increased CD8+ T cell infiltration and effector function, and potently sensitized tumors to anti-PD-1 therapy. Our findings support a dual tumor-suppressive mechanism for GAB3 and propose it as a promising prognostic biomarker and therapeutic target in LUAD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China. Electron…
- Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China; Departme…
- Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China; 4+4 Medi…
Förderung
- National Natural Science Foundation of China
- Beijing Natural Science Foundation
Zitieren
APA
Wang, D., Xiao, C., Fan, T., Deng, Z., Yin, H., Liu, Y., Li, J., Ji, Y., Cai, W., Liao, T., Li, J., Li, C., & He, J. (2026). GAB3 suppresses lung adenocarcinoma progression by inhibiting the MAPK signaling and potentiating CD8+ T cell immunity. Cancer Letters, 651, 218532. https://doi.org/10.1016/j.canlet.2026.218532
Vancouver
Wang D, Xiao C, Fan T, Deng Z, Yin H, Liu Y, et al. GAB3 suppresses lung adenocarcinoma progression by inhibiting the MAPK signaling and potentiating CD8+ T cell immunity. Cancer Letters. 2026;651:218532. doi:10.1016/j.canlet.2026.218532
BibTeX
@article{Wang2026,
author = {Wang, Di and Xiao, Chu and Fan, Tao and Deng, Ziqin and Yin, Hongfei and Liu, Yixiao and Li, Jia and Ji, Yu and Cai, Wenpeng and Liao, Tianle and Li, Jiayan and Li, Chunxiang and He, Jie},
title = {GAB3 suppresses lung adenocarcinoma progression by inhibiting the MAPK signaling and potentiating CD8+ T cell immunity},
journal = {Cancer Letters},
year = {2026},
volume = {651},
pages = {218532},
doi = {10.1016/j.canlet.2026.218532}
}
EUVIMED